Price movement over the last 24 hours
Abbott Laboratories vs JPMorgan Equity Premium Income ETF — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while JPMorgan Equity Premium Income ETF trades at $56.54. The key difference: Abbott Laboratories pays a 2.63% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| ABT | JEPI | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $59.88 |
52-Week Low | $82.57 | $55.29 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
JEPI trades at $56.75, up 0.07% on the day, with a bullish technical signal from moving averages. The ETF's covered-call strategy generates an 8%+ yield, providing income but capping upside potential. Recent news highlights its role as a low-volatility hedge amid muted S&P 500 volatility, though tax efficiency comparisons with peers like SPYI are a focus.
The outlook for JEPI centers on income generation in flat or declining markets, with risks including underperformance in strong bull runs and tax implications on distributions. Its active management offers resilience, but total return may lag the broader market over time.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →